PMC:7534795 / 30490-32766
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T151 | 107-115 | Body_part | denotes | platelet | http://purl.org/sig/ont/fma/fma62851 |
T152 | 258-265 | Body_part | denotes | Heparin | http://purl.org/sig/ont/fma/fma82839 |
T153 | 434-441 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T154 | 450-457 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T155 | 501-506 | Body_part | denotes | heart | http://purl.org/sig/ont/fma/fma7088 |
T156 | 525-532 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T157 | 547-554 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T158 | 620-627 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T159 | 728-735 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T160 | 744-751 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T161 | 916-923 | Body_part | denotes | Heparin | http://purl.org/sig/ont/fma/fma82839 |
T162 | 1415-1422 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T163 | 1757-1759 | Body_part | denotes | h4 | http://purl.org/sig/ont/fma/fma84132 |
T164 | 1857-1865 | Body_part | denotes | alveolar | http://purl.org/sig/ont/fma/fma264783 |
T165 | 1928-1938 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T57 | 501-506 | Body_part | denotes | heart | http://purl.obolibrary.org/obo/UBERON_0000948 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T246 | 84-102 | Disease | denotes | hypercoagulability | http://purl.obolibrary.org/obo/MONDO_0002305 |
T247 | 130-138 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T248 | 308-320 | Disease | denotes | coagulopathy | http://purl.obolibrary.org/obo/MONDO_0001531 |
T249 | 379-387 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T250 | 388-397 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T251 | 481-514 | Disease | denotes | hypertension and/or heart disease | http://purl.obolibrary.org/obo/MONDO_0001302 |
T252 | 481-493 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T253 | 501-514 | Disease | denotes | heart disease | http://purl.obolibrary.org/obo/MONDO_0005267 |
T254 | 816-828 | Disease | denotes | coagulopathy | http://purl.obolibrary.org/obo/MONDO_0001531 |
T255 | 1008-1020 | Disease | denotes | coagulopathy | http://purl.obolibrary.org/obo/MONDO_0001531 |
T256 | 1154-1173 | Disease | denotes | respiratory failure | http://purl.obolibrary.org/obo/MONDO_0021113 |
T257 | 1273-1292 | Disease | denotes | respiratory failure | http://purl.obolibrary.org/obo/MONDO_0021113 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T64675 | 116-126 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T92107 | 354-356 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
T4831 | 501-506 | http://purl.obolibrary.org/obo/UBERON_0000948 | denotes | heart |
T34951 | 501-506 | http://purl.obolibrary.org/obo/UBERON_0007100 | denotes | heart |
T52443 | 501-506 | http://purl.obolibrary.org/obo/UBERON_0015228 | denotes | heart |
T98069 | 501-506 | http://www.ebi.ac.uk/efo/EFO_0000815 | denotes | heart |
T25882 | 947-948 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T68940 | 1754-1756 | http://purl.obolibrary.org/obo/CLO_0001382 | denotes | 48 |
T29687 | 1757-1759 | http://purl.obolibrary.org/obo/CLO_0003599 | denotes | h4 |
T20765 | 1866-1874 | http://purl.obolibrary.org/obo/UBERON_0001637 | denotes | arterial |
T55348 | 1866-1874 | http://www.ebi.ac.uk/efo/EFO_0000814 | denotes | arterial |
T39743 | 2043-2044 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T225 | 258-265 | Chemical | denotes | Heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T226 | 266-279 | Chemical | denotes | anticoagulant | http://purl.obolibrary.org/obo/CHEBI_50249 |
T227 | 434-441 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T228 | 450-457 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T229 | 525-532 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T230 | 547-554 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T231 | 620-627 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T232 | 728-735 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T233 | 744-751 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T234 | 916-923 | Chemical | denotes | Heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T235 | 1105-1118 | Chemical | denotes | anticoagulant | http://purl.obolibrary.org/obo/CHEBI_50249 |
T236 | 1301-1304 | Chemical | denotes | ASA | http://purl.obolibrary.org/obo/CHEBI_15365 |
T237 | 1307-1318 | Chemical | denotes | clopidogrel | http://purl.obolibrary.org/obo/CHEBI_37941 |
T238 | 1321-1330 | Chemical | denotes | tirofiban | http://purl.obolibrary.org/obo/CHEBI_9605 |
T239 | 1333-1345 | Chemical | denotes | fondaparinux | http://purl.obolibrary.org/obo/CHEBI_61033 |
T240 | 1415-1422 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T241 | 1509-1529 | Chemical | denotes | acetylsalicylic acid | http://purl.obolibrary.org/obo/CHEBI_15365 |
T242 | 1525-1529 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T243 | 1531-1534 | Chemical | denotes | ASA | http://purl.obolibrary.org/obo/CHEBI_15365 |
T244 | 1580-1591 | Chemical | denotes | clopidogrel | http://purl.obolibrary.org/obo/CHEBI_37941 |
T245 | 1601-1604 | Chemical | denotes | ASA | http://purl.obolibrary.org/obo/CHEBI_15365 |
T246 | 1609-1620 | Chemical | denotes | clopidogrel | http://purl.obolibrary.org/obo/CHEBI_37941 |
T247 | 1661-1670 | Chemical | denotes | Tirofiban | http://purl.obolibrary.org/obo/CHEBI_9605 |
T248 | 1875-1881 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T249 | 1969-1974 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T80 | 107-126 | http://purl.obolibrary.org/obo/GO_0030168 | denotes | platelet activation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T211 | 0-148 | Sentence | denotes | Table 4 Overview of the pharmacological interventions under investigation targeting hypercoagulability and platelet activation in COVID-19 patients. |
T212 | 149-255 | Sentence | denotes | Pharmacological intervention Sample size and criteria Treatment protocol Key findings Conclusion Reference |
T213 | 256-349 | Sentence | denotes | • Heparin anticoagulant treatment in sepsis-induced coagulopathy • Retrospective cohort study |
T214 | 350-369 | Sentence | denotes | • ≥ 18 years of age |
T215 | 370-397 | Sentence | denotes | • Severe COVID-19 infection |
T216 | 398-463 | Sentence | denotes | • Evaluation of 28-day mortality in heparin and non-heparin users |
T217 | 464-514 | Sentence | denotes | • 48.5% comorbid hypertension and/or heart disease |
T218 | 515-532 | Sentence | denotes | • N = 99 heparin |
T219 | 533-758 | Sentence | denotes | • N = 350 no heparin • Unfractionated (10, 000–15, 000 U/day) or low molecular weight heparin (40–60 mg enoxaparin/day) for 7 days or longer • No difference in 28-day mortality endpoint between heparin and non-heparin users. |
T220 | 759-869 | Sentence | denotes | • Lower 28-day mortality in patients with sepsis-induced coagulopathy (SIC) score of ≥4 in stratified analysis |
T221 | 870-1085 | Sentence | denotes | • Odd Ratio (OR) 0.372 (95% CI 0.154–0.901) • Heparin may be associated with a lower 28-day mortality rate only in patients with enhanced coagulopathy risk such as SIC score of 4 or greater (Tang, Bai, et al., 2020) |
T222 | 1086-1240 | Sentence | denotes | • Antiplatelet and anticoagulant combination therapy for hypoxemia, respiratory failure, and cardiac adverse events • Case control, proof-of-concept study |
T223 | 1241-1292 | Sentence | denotes | • Adult patients with hypoxemic respiratory failure |
T224 | 1293-1361 | Sentence | denotes | • N = 5 ASA + clopidogrel + tirofiban + fondaparinux + standard care |
T225 | 1362-1422 | Sentence | denotes | • N = 5 matched controls given low molecular weight heparin |
T226 | 1423-1493 | Sentence | denotes | • Secondary outcome included major and minor cardiac adverse events 1. |
T227 | 1494-1600 | Sentence | denotes | Single dose of acetylsalicylic acid (ASA) 250 mg i.v. and single loading dose of oral clopidogrel 300 mg2. |
T228 | 1601-1660 | Sentence | denotes | ASA and clopidogrel continued at 75 mg orally for 30 days3. |
T229 | 1661-1760 | Sentence | denotes | Tirofiban 25 μg/kg as bolus i.v. injection, then 0.15 μg/kg/min continuous i.v. infusion for 48 h4. |
T230 | 1761-1890 | Sentence | denotes | Fondaparinux 2.5 mg/day s.c. for the duration of the hospital stay • Significant improvement in alveolar-arterial oxygen gradient |
T231 | 1891-1944 | Sentence | denotes | • Significant improvement in CRP and lymphocyte count |
T232 | 1945-2078 | Sentence | denotes | • Patients in treatment group did not experience any cardiac adverse events • Small study and not a randomized controlled trial (RCT) |
T233 | 2079-2276 | Sentence | denotes | • Intensive antithrombotic therapy may be useful in patients with severe respiratory distress with prothrombotic state at risk for acute cardiac events (Viecca, Radovanovic, Forleo, & Santus, 2020) |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T125 | 84-102 | Phenotype | denotes | hypercoagulability | http://purl.obolibrary.org/obo/HP_0100724 |
T126 | 293-299 | Phenotype | denotes | sepsis | http://purl.obolibrary.org/obo/HP_0100806 |
T127 | 308-320 | Phenotype | denotes | coagulopathy | http://purl.obolibrary.org/obo/HP_0003256 |
T128 | 481-493 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T129 | 801-807 | Phenotype | denotes | sepsis | http://purl.obolibrary.org/obo/HP_0100806 |
T130 | 816-828 | Phenotype | denotes | coagulopathy | http://purl.obolibrary.org/obo/HP_0003256 |
T131 | 1008-1020 | Phenotype | denotes | coagulopathy | http://purl.obolibrary.org/obo/HP_0003256 |
T132 | 1143-1152 | Phenotype | denotes | hypoxemia | http://purl.obolibrary.org/obo/HP_0012418 |
T133 | 1154-1173 | Phenotype | denotes | respiratory failure | http://purl.obolibrary.org/obo/HP_0002878 |
T134 | 1273-1292 | Phenotype | denotes | respiratory failure | http://purl.obolibrary.org/obo/HP_0002878 |
T135 | 2152-2172 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
2_test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
33031856-32220112-84038872 | 1080-1084 | 32220112 | denotes | 2020 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
965 | 1920-1923 | Gene | denotes | CRP | Gene:1401 |
966 | 787-795 | Species | denotes | patients | Tax:9606 |
967 | 985-993 | Species | denotes | patients | Tax:9606 |
968 | 1249-1257 | Species | denotes | patients | Tax:9606 |
969 | 2131-2139 | Species | denotes | patients | Tax:9606 |
970 | 258-265 | Chemical | denotes | Heparin | MESH:D006493 |
971 | 434-441 | Chemical | denotes | heparin | MESH:D006493 |
972 | 450-457 | Chemical | denotes | heparin | MESH:D006493 |
973 | 547-554 | Chemical | denotes | heparin | MESH:D006493 |
974 | 599-627 | Chemical | denotes | low molecular weight heparin | MESH:D006495 |
975 | 728-735 | Chemical | denotes | heparin | MESH:D006493 |
976 | 744-751 | Chemical | denotes | heparin | MESH:D006493 |
977 | 916-923 | Chemical | denotes | Heparin | MESH:D006493 |
978 | 1509-1529 | Chemical | denotes | acetylsalicylic acid | MESH:D001241 |
979 | 1531-1534 | Chemical | denotes | ASA | MESH:D001241 |
980 | 1580-1591 | Chemical | denotes | clopidogrel | MESH:D000077144 |
981 | 1601-1604 | Chemical | denotes | ASA | MESH:D001241 |
982 | 1609-1620 | Chemical | denotes | clopidogrel | MESH:D000077144 |
983 | 1661-1670 | Chemical | denotes | Tirofiban | MESH:D000077466 |
984 | 1761-1773 | Chemical | denotes | Fondaparinux | MESH:D000077425 |
985 | 1875-1881 | Chemical | denotes | oxygen | MESH:D010100 |
986 | 293-299 | Disease | denotes | sepsis | MESH:D018805 |
987 | 308-320 | Disease | denotes | coagulopathy | MESH:D001778 |
988 | 379-387 | Disease | denotes | COVID-19 | MESH:C000657245 |
989 | 421-430 | Disease | denotes | mortality | MESH:D003643 |
990 | 481-493 | Disease | denotes | hypertension | MESH:D006973 |
991 | 501-519 | Disease | denotes | heart disease • N | MESH:D006331 |
992 | 701-710 | Disease | denotes | mortality | MESH:D003643 |
993 | 774-783 | Disease | denotes | mortality | MESH:D003643 |
994 | 801-807 | Disease | denotes | sepsis | MESH:D018805 |
995 | 816-828 | Disease | denotes | coagulopathy | MESH:D001778 |
996 | 830-833 | Disease | denotes | SIC | MESH:D018805 |
997 | 962-971 | Disease | denotes | mortality | MESH:D003643 |
998 | 1008-1020 | Disease | denotes | coagulopathy | MESH:D001778 |
999 | 1034-1037 | Disease | denotes | SIC | MESH:D018805 |
1000 | 1143-1152 | Disease | denotes | hypoxemia | MESH:D000860 |
1001 | 1154-1173 | Disease | denotes | respiratory failure | MESH:D012131 |
1002 | 1273-1296 | Disease | denotes | respiratory failure • N | MESH:D012131 |
1003 | 2152-2172 | Disease | denotes | respiratory distress | MESH:D012128 |
1007 | 139-147 | Species | denotes | patients | Tax:9606 |
1008 | 84-102 | Disease | denotes | hypercoagulability | MESH:D019851 |
1009 | 130-138 | Disease | denotes | COVID-19 | MESH:C000657245 |